Etolac (Etodolac)

Quick links

Choose a section

Quick links to important sections

Advertisements

Etolac (Etodolac)

Advertisements
Advertisements

Overview of Etolac (Etodolac)

Quick Facts

Property Description
Active ingredient Etodolac (S-enantiomer is primary active form)
Form Tablet, Capsule, Extended-Release Tablet
Pharmacological class Nonsteroidal Anti-Inflammatory Drug (NSAID)
Common use Relief of pain and inflammation
Origin Synthetic (Pyranocarboxylic acid derivative)

What Type of Medicine is Etodolac? (Identity and Classification)

Etolac, a common trade name for the active substance Etodolac, is a synthetic medicine whose identity is defined by its International Nonproprietary Name (INN), Etodolac. It is categorized as a Nonsteroidal Anti-Inflammatory Drug (NSAID) and is classified chemically as a pyranocarboxylic acid derivative, placing it within the acetic acid subclass. The active substance is administered as a racemic mixture; however, the S-form is known to be the biologically active component that delivers the core therapeutic effects. As a prescription-only drug, Etodolac is clinically recognized for its efficient absorption following oral administration, making it a small molecule intended for systemic management.

Etodolac: A Preferential COX-2 Inhibitor (General Purpose)

The general purpose of Etodolac is to provide analgesic and anti-inflammatory activities. It functions by inhibiting prostaglandin synthesis, reducing the concentration of chemical messengers responsible for triggering pain, swelling, and fever. Etodolac is noted for its preferential selectivity toward the Cyclooxygenase-2 (COX-2) enzyme, distinguishing it from older, less selective NSAIDs. This mechanism enables the medication to reduce discomfort associated with inflammatory processes, such as the symptoms experienced during episodes of arthritis.

Forms of Etodolac for Oral Administration (Physical Presentation)

Etodolac is supplied as a solid preparation for oral administration, provided in standard tablets and capsules. A distinctive feature is the availability of specialized extended-release formulations (often branded as "XL" versions), which are designed to provide a sustained delivery of the active ingredient over a longer period. These physical forms contain the active ingredient Etodolac alongside solid pharmaceutical excipients, which facilitate its effective release and systemic absorption.

Regulatory References

  1. Etodolac (Lodine) Drug Information
Advertisements

What side effects are possible with Etolac (Etodolac)?

Possible Side Effects and Safety Information

Etolac (Etodolac) is associated with systemic safety characteristics and adverse reactions documented in official regulatory labeling, consistent with its classification as a nonsteroidal anti-inflammatory drug (NSAID).


Serious Adverse Reactions and Systemic Warnings

Regulatory documents include the most serious safety warnings concerning cardiovascular thrombotic events, which can include myocardial infarction (MI) and stroke. These risks may increase with the duration of use. A second major warning concerns gastrointestinal (GI) adverse events, specifically the potential for bleeding, ulceration, and perforation of the stomach or intestines, which may occur without prior symptoms. Severe and potentially fatal reactions affecting the skin (e.g., Stevens-Johnson Syndrome) and liver (hepatotoxicity) are also documented.

Common Adverse Reactions

The most frequently reported side effects are concentrated in the Gastrointestinal System, and are often classified as Common (1% to 10% incidence). These include dyspepsia, abdominal pain, constipation, diarrhea, nausea, and vomiting. Common effects also affect the Nervous System (e.g., dizziness, headache) and include edema (swelling) and tinnitus.

Safety Constraints and Special Populations

The medication is contraindicated for treating pain following coronary artery bypass graft (CABG) surgery. Use at 20 weeks gestation and later is associated with risks of fetal renal dysfunction, and older adults are recognized in labeling as being at a greater risk for serious GI adverse events. Use is generally restricted in individuals with severe pre-existing cardiac, renal, or hepatic failure.

Advertisements

Overdose and Emergency Response

Overdose of Etolac (Etodolac) is characterized by documented Central Nervous System (CNS) and Gastrointestinal (GI) manifestations. Official regulatory descriptions of overdose symptoms include general signs such as drowsiness, dizziness, nausea, vomiting, and stomach pain. Severe, life-threatening outcomes are associated with significant escalation of symptoms, including signs of gastrointestinal bleeding—indicated by bloody, black, or tarry stools or vomit resembling coffee grounds—and central effects such as coma and respiratory depression.

Regulatory guidance requires immediate action if an overdose is suspected. Urgent medical attention is mandated when the affected individual exhibits critical signs, which explicitly include collapsing, trouble breathing, having a seizure, or inability to be awakened. Immediate contact with emergency services or a Poison Control Helpline is a required step.

In accordance with official labeling, no specific antidote is known for Etodolac. Therefore, management is defined as providing symptomatic and supportive care to maintain vital functions. Supportive measures may include the use of oral activated charcoal to help reduce systemic absorption of the drug. Regulatory documents also note that older adults are at greater risk for serious gastrointestinal adverse events, which constitutes a major severe manifestation of overdose.

Advertisements

Therapeutic Uses of Etolac (Etodolac)

Understanding Etodolac

Etolac, which contains the active ingredient etodolac, is a nonsteroidal anti-inflammatory drug (NSAID). It is primarily used to manage pain and reduce inflammation in various musculoskeletal conditions. By inhibiting the production of certain chemicals in the body that cause inflammation, it helps alleviate discomfort and improves physical function in patients with chronic or acute inflammatory states.

Main Therapeutic Uses

Etodolac is frequently utilized for the management of symptoms associated with long-term joint disorders. Its primary applications include:

  • Osteoarthritis: It helps manage the joint pain and stiffness caused by the breakdown of cartilage, particularly in weight-bearing joints like the knees and hips.
  • Rheumatoid Arthritis: It is used to reduce the swelling, pain, and joint tenderness associated with this chronic autoimmune inflammatory condition.
  • Acute Pain Management: Beyond chronic conditions, etodolac is indicated for the treatment of short-term, acute pain, such as that following minor surgical procedures or musculoskeletal injuries.

Key Benefits

The clinical use of etodolac offers several benefits for patients dealing with inflammatory pain:

  • Reduction of Inflammation: By targeting the inflammatory response, it helps decrease visible swelling and internal tissue irritation.
  • Improved Mobility: By reducing pain and stiffness in the joints, it can help patients maintain a higher level of daily activity and physical independence.
  • Symptomatic Relief: It provides consistent management of discomfort, allowing for better quality of life during both flare-ups and routine management of chronic diseases.

Regulatory References

  1. NIH DailyMed
Advertisements

Eligibility and Restrictions for Use

Official Eligibility Rules for Etolac (Etodolac)

Official regulatory documents define strict criteria regarding which populations can and cannot use Etolac. Use is generally established for adults 18 years and older.


Absolute Contraindications (Must Not Use)

Etolac is contraindicated and must not be used by patients who have a known hypersensitivity to Etodolac or any other NSAID or Aspirin, especially if prior use resulted in asthma or allergic reactions. It is also prohibited for patients in the setting of Coronary Artery Bypass Graft (CABG) surgery and for women who are 30 weeks gestation or later in pregnancy.


Age and Condition-Based Restrictions

Pediatric use is highly restricted. Safety and effectiveness are not established for the immediate-release form in patients under 18 years of age. The extended-release form has established use only for pediatric patients 6 to 16 years old specifically for Juvenile Rheumatoid Arthritis.

Use is strongly not recommended in patients with advanced renal disease or severe heart failure. Caution is required in the elderly and in patients with a history of gastrointestinal disease or hypertension. Use during lactation is generally not recommended as excretion into breast milk is unknown.

Advertisements

What should I know about interactions with other medicines?

Etolac, as a nonsteroidal anti-inflammatory drug (NSAID), is known to interact with certain other medications, primarily by affecting kidney function or increasing the risk of bleeding.

Potential Drug Interactions

Interacting Product Category Potential Effect Interaction Concern
Anticoagulants (e.g., Warfarin) and Anti-platelets (e.g., Aspirin) Increased risk of serious gastrointestinal (GI) bleeding and ulceration. Avoid combination unless closely monitored. Coadministration with Aspirin is generally not recommended.
Other NSAIDs (including COX-2 inhibitors) Increased risk of GI adverse effects. Avoid concomitant use of two or more NSAIDs.
Diuretics (e.g., Furosemide, Thiazides), ACE-Inhibitors, Angiotensin Receptor Blockers (ARBs) NSAIDs may diminish the antihypertensive and diuretic effects and increase the risk of renal function deterioration. Use with caution, especially in the elderly or volume-depleted patients. Monitor kidney function.
Lithium and Methotrexate Etolac may cause elevated blood levels of Lithium and Methotrexate by reducing their clearance. Monitor closely for signs of toxicity.
Cyclosporine and Digoxin May lead to elevated serum levels and enhanced toxicity of these drugs, especially in patients with altered kidney function. Monitor closely for specific toxicities.

Other Interactions

Concomitant use of Etolac with alcohol or corticosteroids also significantly increases the risk of serious GI bleeding. Antacids may decrease the maximum concentration of Etolac in the blood but do not affect the total amount absorbed.

Advertisements

Mechanism of Action

How Etolac (Etodolac) Works

Etodolac functions as a reversible inhibitor of the Cyclooxygenase (COX) enzymes, specifically exhibiting preferential selectivity for the COX-2 isoenzyme over COX-1. The active S-enantiomer binds to the enzyme's active site, restricting the conversion of arachidonic acid into prostaglandins (PGE2). This molecular cascade results in the modulation of the inflammatory cascade, reducing the physiological consequences of vasodilation and increased capillary permeability at sites of tissue reaction.

The reduction in prostaglandins mediates a two-fold effect on signaling. Peripherally, lower PGE2 levels alter the chemical sensitization of nociceptors (pain receptors), reducing the amplification of afferent signal transmission. Centrally, this mechanism modulates the hypothalamic thermal set point. The mechanism retains a degree of COX-1 interaction, which affects pathways responsible for homeostatic physiological functions like gastric prostaglandin synthesis and renal blood flow regulation.

Advertisements

Dosage and Administration Information

How to Use Etolac (Etodolac)

Etodolac is an oral medication administered according to specific regimens defined by its formulation and the condition being addressed. It is available as immediate-release (IR) capsules/tablets and specialized extended-release (ER) tablets.

Administration and Dosing Principles

The immediate-release (IR) forms are typically dosed in the range of 200 mg to 500 mg per administration. When used for acute pain, IR doses are often scheduled every 6 to 8 hours, as a divided regimen. The total daily intake of the immediate-release form must not exceed 1000 mg.

For the management of chronic conditions, the extended-release (ER) tablets are designed for once-daily use, with dosages ranging from 400 mg to 1000 mg. The maximum allowed daily dose for the extended-release formulation is 1200 mg.

Essential Procedural Requirements

Intake Condition: Etodolac may be taken with food or a large amount of water to assist with patient tolerance, though absorption is not significantly affected. Extended-release tablets must be swallowed whole and should not be crushed, broken, or chewed, as this compromises the controlled-release mechanism.

Population-Specific Dosing: In older adults (65 and over), therapy is typically initiated at the lowest effective dose. For pediatric patients (6 to 16 years old) with Juvenile Rheumatoid Arthritis, only the extended-release form is approved, administered once daily at a weight-based dose.

Advertisements

Recent Clinical Evidence

Research Evidence / Overview of Studies for Etolac (Etodolac)

Evidence for Use in Osteoarthritis

Research for Etolac in the context of Osteoarthritis primarily consists of Randomized Controlled Trials (RCTs) and comparative studies where patients were observed over defined time intervals. These studies were used in research exploring how symptoms change over time, focusing on populations of adults and older adults. Researchers monitored outcomes related to physical discomfort, such as patient-reported measures of pain intensity, and outcomes reflecting daily functioning or activity level.

Findings describe patterns observed in the studies regarding shifts in pain intensity and functional scores. Evidence was also derived from comparisons to other established medicines in the same class, and these studies report how symptoms evolved in the observed populations with often similar patterns in the measured outcomes.


Evidence for Use in Rheumatoid Arthritis

Etolac was studied for Rheumatoid Arthritis using high-quality research designs, including RCTs and comparative trials involving adults and older adults. Studies explored how symptoms evolved in the observed populations, monitoring outcomes capturing phases of heightened symptom activity, such as joint pain, tenderness, swelling, and morning stiffness. The data show patterns related to shifts in the reported measurements over study periods that typically lasted up to six months.


Evidence for Use in Acute Pain and Short-Term Relief

For the indication of acute or disruptive episodes of mild to moderate pain, research mainly consists of short-term, single-dose RCTs. Research exploring short-term symptom changes was evaluated in adult populations, and the primary focus was on outcomes describing episodic or acute changes, such as the time it takes for symptomatic change to be observed. Since this medicine is only studied and used for temporary symptom assistance, the research only applies to short-term needs.


What is Still Uncertain About Etolac (Etodolac) Research

The evidence landscape contributes to the evidence landscape based on numerous short- and intermediate-term studies, but certain gaps exist.

  • Long-term patterns are not fully established: There is limited information for long-term outcomes (e.g., outcomes over multiple years) that track durable changes in patient function or how symptoms evolve past the typical six-month trial window.
  • Limited insight into disease markers: Most studies concentrated on patient-reported outcomes describing perceived discomfort (pain and function) rather than extensive investigation into long-term disease progression biomarkers.

Key Studies & References Etodolac Oral Tablet, Capsule, Extended-Release Tablet Labeling and Drug Information (Official FDA Prescribing Information Summary)

Advertisements

Frequently Asked Questions (FAQ)

Common questions about Etolac (Etodolac) (FAQ)

Q: What is Etolac (Etodolac) and how does it work?

A: Etolac (Etodolac) is a prescription nonsteroidal anti-inflammatory drug (NSAID). It is used to relieve pain, swelling, and inflammation. Etolac works by blocking certain natural substances in the body (called cyclooxygenase or COX enzymes) that contribute to inflammation, fever, and pain. It is used to treat conditions like osteoarthritis, rheumatoid arthritis, and general acute pain.


Q: Does Etolac (Etodolac) have a risk of serious side effects?

A: Yes, like all NSAIDs, Etolac carries a risk of serious side effects. The most serious warnings relate to the stomach and intestines and the heart and blood vessels.

  • Serious Stomach and Intestine Issues: Etolac can increase the risk of serious side effects like bleeding, ulcers, and holes (perforations) in the stomach or intestines. These can be fatal and may occur without warning symptoms. The risk is higher for older adults, people taking blood thinners, or those with a history of stomach problems.
  • Serious Cardiovascular Issues: Etolac can increase the risk of heart attack and stroke, which can be fatal. This risk may be higher if you use the medicine for a long time or at high doses, and is especially a concern for people who already have heart disease or risk factors for it. Etolac should not be used right before or after a type of heart surgery called Coronary Artery Bypass Graft (CABG).

If you experience symptoms such as chest pain, sudden weakness, black or tarry stools, or vomiting that looks like coffee grounds, seek emergency medical help immediately.


Q: What are the common side effects of Etolac (Etodolac)?

A: The more common side effects that may occur with Etolac include:

  • Nausea, vomiting, or indigestion
  • Stomach pain, gas, or diarrhea
  • Dizziness
  • Headache
  • Constipation
  • Blurred vision
  • Tinnitus (ringing or buzzing in the ears)

Consult your healthcare provider if any of these side effects are persistent or bothersome.


Q: Can I take Etolac (Etodolac) with other pain relievers like ibuprofen or aspirin?

A: No, you should not take Etolac with other NSAID pain relievers, such as ibuprofen, naproxen, or regular aspirin, unless directed by your healthcare provider. Taking multiple NSAIDs together increases your risk of serious side effects, especially stomach bleeding and cardiovascular problems. Always check the labels of over-the-counter medicines, as many contain NSAIDs.

However, a low-dose aspirin for heart protection may be used if specifically advised by your healthcare provider; they will need to monitor you closely.


Q: Is Etolac (Etodolac) safe to take during pregnancy?

A: Do not take Etolac at or after 20 weeks of pregnancy unless specifically instructed to do so by your doctor. Taking NSAIDs around this time can cause serious harm to the unborn baby's kidneys and heart. If you are pregnant or plan to become pregnant, discuss the risks and benefits with your healthcare provider.

Advertisements

How should Etolac (Etodolac) be stored and disposed of?

Storage and Disposal of Etodolac

The storage of Etodolac is defined by regulatory requirements to preserve product quality. Tablets and capsules must be stored at Controlled Room Temperature, which ranges from 20 C to 25 C (68 F to 77 F), with brief excursions allowed up to 30 C. The product must be kept in a tightly closed container, away from both moisture and freezing temperatures, to prevent degradation.

All forms of Etodolac must be stored out of the sight and reach of children.

Regarding disposal, Etodolac is not listed as a medication recommended for flushing down the toilet. Unused or expired medication should be returned to a local drug take-back program. If a take-back option is unavailable, the medication should be mixed with an unappealing substance (such as dirt) and placed into a sealed container before being discarded in the household trash, according to official guidelines.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Etolac (Etodolac) found in:

A-Z Index: